FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 684 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Company Gives Cancer Patient a New HVAC System After Treatment and... March 8, 2019 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Easy Meals at Home October 23, 2020 A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... July 11, 2024 Load more HOT NEWS Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... What to Say to Someone With Cancer: A Patient Perspective Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory...
